KYOWA HAKKO KIRIN CO., LTD.;LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
发明人:
GRANGER, STEVEN W.,史帝文Ｗ 格瑞杰,史帝文Ｗ 格瑞傑,KATO, SHINICHIRO,加藤慎一郎,WARE, CARL F.,卡尔Ｆ 威尔,卡爾Ｆ 威爾,史帝文W 格瑞杰,史帝文W 格瑞傑,卡尔F 威尔,卡爾F 威爾
申请号：
TW096131608
公开号：
TWI405771B
申请日:
2007.08.24
申请国别(地区):
TW
年份:
2013
代理人:
摘要：
Provided herein are antibodies, such as fully human antibodies, that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided are methods of making antibodies, such as fully human antibodies, that that immunospecifically bind to a hLIGHT polypeptide. Also provided herein is a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject an antibody, such as a fully human antibody, that immunospecifically binds to a hLIGHT polypeptide. In preferred embodiments, that anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.本發明提供免疫專一性結合至hLIGHT多肽抗體，諸如完全人類抗體。本發明亦提供編碼免疫專一性結合至hLIGHT多肽抗體(諸如完全人類抗體)的經分離核酸。本發明另外提供包含編碼免疫專一性結合至hLIGHT多肽抗體(諸如完全人類抗體)之核酸之載體及宿主細胞。本發明亦提供製造免疫專一性結合至hLIGHT多肽抗體(諸如完全人類抗體)之方法。本發明亦提供治療受檢者體內由hLIGHT介導之疾病之方法，包含向該受檢者投與免疫專一性結合至hLIGHT多肽抗體(諸如完全人類抗體)。在較佳實施例中，本發明所提供之抗hLIGHT抗體將改善、中和或抑制活體內hLIGHT生物活性(例如來自表現hLIGHT受體之細胞之hLIGHT介導的CCL20、IL-8或RANTES的產生或分泌)。本發明亦提供一種偵測檢體中hLIGHT之方法，以及一種改善、中和或抑制例如患有hLIGHT活性有害之病症之人類受檢者體內的hLIGHT活性之方法。
